Novartis (NVS) said Friday that final results from a phase III study supported a slowing decline in kidney function in adults with IgA nephropathy, a progressive autoimmune kidney disease, who were treated with Vanrafia, or atrasentan.
Data showed "clinically meaningful results" with Vanrafia, compared with placebo in estimated glomerular filtration rate change from baseline at the end of study treatment at week 132, the company said.
Novartis said safety was consistent with prior findings.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.